A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas

Modern Pathology

Volumn 24, Issue 7, 2011, Pages 974-982

  Dias Santagata, Dora ^a   Lam, Quynh ^a   Bergethon, Kristin ^a   Baker, Gabrielle M ^a   Iafrate, A John ^a   Rakheja, Dinesh ^b   Hoang, Mai P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

adnexal neoplasm; EGFR; gene mutation; metastasis; PIK3CA; TP53

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PROTEIN P53; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; APOCRINE CARCINOMA; ARTICLE; CANCER MORTALITY; CARCINOGENESIS; CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DIGITAL PAPILLARY ADENOCARCINOMA; ECCRINE CARCINOMA; ECCRINE POROCARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; METASTASIZING ADNEXAL CARCINOMA; MOLECULARLY TARGETED THERAPY; PIK3CA TUMOR GENE; PRIMARY TUMOR; PRIORITY JOURNAL; SKIN METASTASIS; SWEAT GLAND CARCINOMA; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DNA MUTATIONAL ANALYSIS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SWEAT GLAND NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959921749     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.48     Document Type: Article

References (46)

1. Schroder U, Dries V, Klussmann JP, et al. Successful adjuvant tamoxifen therapy for estrogen receptorpositive metastasizing sweat gland adenocarcinoma: need for a clinical trial? Ann Otol Rhinol Laryngol 2004;113:242-244. (Pubitemid 38337772)
2. Nash JW, Barrett TL, Kies M, et al. Metastatic hidradenocarcinoma with demonstration of Her-2/ neu gene amplification by fluorescence in situ hybridization: potential treatment implications. J Cutan Pathol 2007;34:49-54. (Pubitemid 46066527)
3. Battistella M, Mateus C, Lassau N, et al. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J Eur Acad Dermatol Venereol 2010;24:199-203.
4. Wong TY, Suster S, Nogita T, et al. Clear cell eccrine carcinomas of the skin: a clinicopathologic study of nine patients. Cancer 1994;73:1631-1643. (Pubitemid 24085263)
5. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648. (Pubitemid 29415219)
6. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345. (Pubitemid 38944402)
7. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
8. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosinase kinase inhibitors. Cancer Cell 2006;10:25-38.
9. Li D, Ambrogo L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27: 4702-4711.
10. Riely GJ. Second-generation epidermal growth factor receptor tyrosinase kinase inhibitors in non-small cell lung cancer. J Thorac Oncol 2008;3(Suppl 2): S146-S149. (Pubitemid 351786747)
11. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005;13: 205-220. (Pubitemid 41209013)
12. Holden JA, Willmore-Payne C, Layfield LJ. Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology. Exp Mol Pathol 2008;85:68-75.
13. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expression mutations in KIT. Br J Cancer 2010;102:1219-1223.
14. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774. (Pubitemid 46630941)
15. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumors: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2:146-158.
16. Janisson-Dargaud D, Durlach A, Lorenzato M, et al. Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma. J Cutan Pathol 2008;35:916-921.
17. Torres-Cabala CA, Wang W-L, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acrallentiginous/ mucosal type. Mod Pathol 2009;22: 1446-1456.
18. Growdon WB, Boisvert SL, Akhavanfard S, et al. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol 2008;111:289-297.
19. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82. (Pubitemid 43740454)
20. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-775. (Pubitemid 41351083)
21. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008;452: 553-563. (Pubitemid 351483369)
22. Turke AB, Engelman JA. PIKing the right patient. Clin Cancer Res 2010;169:3523-3525.
23. Ihle NT, Lemos Jr R, Wipf P, et al. Mutations in the phophatidylinositol- 3-kinase pathway predict for antitumor activity of the inhibitot PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009;69:143-150.
24. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-8030.
25. Michelucci A, Cristofano CD, Lami A, et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 2009;18: 200-205.
26. Wang Y, Helland A, Holm R, et al. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005; 25:322.
27. Samuels Y,Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
28. Berns EM, Klijn JG, Smid M, et al. TP53 and myc gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer 1996;16:170-179. (Pubitemid 26231064)
29. Elledge RM, Allred DC. The P53 tumor suppressor genes in breast cancer. Breast Cancer Res Treat 1994;32:39-47. (Pubitemid 24322246)
30. Hollstein M, Sidransky D, Vogelstain B, et al. p53 mutations in human cancer. Science 1991;253:49-53.
31. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331. (Pubitemid 27131374)
32. Biernat W, Peraud A, Wozniak L, et al. p53 mutations in sweat gland carcinomas. Int J Cancer 1998;76: 317-320. (Pubitemid 28282927)
33. Takata M, Hashimoto K, Mehregan P, et al. Genetic changes in sweat gland carcinomas. J Cutan Pathol 2000;27:30-35. (Pubitemid 30018921)
34. Takata M, Rehman I, Rees JL. A trichilemmal carcinoma arising from a proliferating trichilemmal cyst: the loss of the wild-type p53 is a critical event in malignant transformation. Hum Pathol 1998;29:193-195. (Pubitemid 28099519)
35. Kazakov DV, Ivan D, Kutzner H, et al. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation. Am J Dermatopathol 2009;31:236-247.
36. Rapakko K, Allinen M, Syrjakoski K, et al. Germline TP53 alterations in Finish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 2001;84:116-119. (Pubitemid 32102515)
37. Ruijs MWG, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 2010;47:421-428.
38. Kuenen-Boumeester V, Henzen-Logmans SC, Timmermans MM, et al. Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast. J Pathol 1999;189:169-175. (Pubitemid 29448908)
39. Piris A, Scopsi L, Clemente C, et al. Epidermal growth factor receptor gene status by fluorescent in situ hybridization in malignant, atypical, and benign hidradenomas. Am J Dermatopathol 2010;32:586-592.
40. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):9-15.
41. Gupta R, Dastane AM, Forozan F, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol 2009;22:128-133.
42. Bell DW, Lunch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-8092. (Pubitemid 46657411)
43. Sone T, Kasahara K, Kimura H, et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer 2007;109:1836-1844. (Pubitemid 46668548)
44. Kersting C, Tidow N, Schmidt H, et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of EGFR amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 2004;84:582-587. (Pubitemid 38858467)
45. Simon R, Panussis S, Maurer R, et al. KIT (CD-117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004;10:178-183. (Pubitemid 38114177)
46. Holst VA, Marshall CE, Moskaluk CA, et al. KIT protein expression and analysis of c-kit mutation in adenoid cystic carcinoma. Mod Pathol 1999;12: 956-960. (Pubitemid 29485269)